Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rivian Automotive, Inc. (RIVN) vs Smith & Nephew plc (SNN) Price & Performance

Rivian Automotive, Inc.Trade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Rivian Automotive, Inc. vs Smith & Nephew plc — how do they compare? Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Smith & Nephew plc for 120 Days on average.

RIVNSNN
Market Cap
$20.75B$11.10B
Volume
26,144,6541,051,703
Sector
Consumer CyclicalHealth
52-Week High
$22.45$37.17
52-Week Low
$12.50$26.42
Typical Hold Time
61 Days120 Days
Enterprise Value
$20.79B$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rivian Automotive, Inc.

Rivian Automotive (RIVN) trades at $14.03, down 2.16% amid bearish technical signals despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving revenue trends and cash flow reduction. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show selling pressure with RSI near oversold levels.

Rivian presents a high-risk growth opportunity with significant operational improvements but persistent losses. The R2 SUV rollout and autonomy technology development offer long-term potential, while near-term challenges include cash burn and competitive EV market pressures. Investors should weigh improving fundamentals against substantial execution risks in a capital-intensive industry.

Smith & Nephew plc

SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.

The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rivian Automotive, Inc.

Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.

Read more on RIVN →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →